ABBV AbbVie Inc.
Company Analysis
Latest News
AbbVie Enters Licensing Deal with Zelgen Biopharma for Cancer Drug Alveltamig
AbbVie partnered with Zelgen Biopharma to develop and commercialize Alveltamig. The drug is currently under investigation as a treatment for various blood...
Court Blocks US 340B Drug Rebate Program, Impacting AbbVie and Other Drugmakers
A federal judge issued a preliminary injunction, temporarily blocking the U.S. government’s 340B Rebate Model Pilot Program. The program was scheduled to...
AbbVie Sees December Analyst Upgrades Amidst Pipeline Progress and Drug Pricing Scrutiny
AbbVie entered December 30, 2025, following a strong year, buoyed by positive analyst sentiment in December with upgrades from HSBC and Morgan Stanley raising...
AbbVie Awaits Imminent U.S. Drug Pricing Deal Post-Holidays
The primary focus for AbbVie on December 27, 2025, centers on the anticipated drug-pricing deal with the U.S. government. Reports from December 22 and December...
AbbVie Terminates ABBV-303 Oncology Study Ahead of Q3 Earnings
On October 24, 2025, AbbVie terminated its Phase 1 clinical trial of ABBV-303 for advanced solid tumors, a move that may affect its oncology pipeline and...
AbbVie Secures Rinvoq Exclusivity until 2037 Through Legal Settlements
AbbVie has reached legal settlements that will delay the market entry of generic versions of its key immunology drug, Rinvoq, until 2037. This development...
AbbVie's Investigational Kidney Disease Therapy Receives FDA Fast Track Designation
AbbVie, in collaboration with Calico Life Sciences, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to...
AbbVie CEO Supports Potential US Probe into Foreign Drug Pricing
AbbVie's CEO, Robert Michael, has voiced support for potential new U.S. trade measures aimed at foreign drug pricing. His comments came as reports emerged that...
AbbVie's Rinvoq Shows Superiority Over Humira in Head-to-Head Rheumatoid Arthritis Study
AbbVie announced positive topline results from its Phase 3b/4 SELECT-SWITCH study, a head-to-head trial comparing Rinvoq (upadacitinib) to Humira (adalimumab)...
AbbVie completes Bretisilocin acquisition; FDA expands RINVOQ label
On October 17, 2025, AbbVie announced the completion of its acquisition of Gilgamesh Pharmaceuticals' Bretisilocin, a move seen as strengthening its...
ABBV edges lower as investors digest strong Q2 earnings and guidance hike
AbbVie Inc. closed at $226.22 on October 15, 2025, down 1.27% from the previous session, continuing a modest decline over the past week despite strong business...
AbbVie Faces Potential Patent Battle Over Newly Acquired Depression Drug
AbbVie is facing a potential legal challenge from Enveric Biosciences (NASDAQ: ENVB) regarding its recently acquired major depressive disorder candidate,...
AbbVie Set for $1.64 Dividend Payout; Ex-Dividend Date October 15, 2025
AbbVie Inc. (ABBV) will go ex-dividend on October 15, 2025, with shareholders of record set to receive a $1.64 per share dividend payable on November 14, 2025....
AbbVie Gains FDA Approval for Expanded Rinvoq Use; New Oncology Data to Be Presented at ESMO
On October 13, 2025, AbbVie announced that the FDA approved an updated indication for Rinvoq, allowing broader use in adults with moderately to severely active...
AbbVie's RINVOQ Receives FDA Approval for Expanded Use in IBD Treatment
The U.S. Food and Drug Administration (FDA) has approved an updated indication for AbbVie's RINVOQ (upadacitinib) for the treatment of adults with moderately...
AbbVie to Present New Oncology Data at ESMO; FDA Expands Rinvoq Indication
On October 13, 2025, AbbVie announced it will present new data from its antibody-drug conjugate (ADC) platform at the upcoming ESMO 2025 Congress, highlighting...
AbbVie Announces FDA Approval for RINVOQ and New Oncology Data Presentation
On October 13, 2025, AbbVie Inc. announced two significant developments: the FDA approved an updated indication statement for RINVOQ, expanding its use for...
AbbVie Receives Expanded FDA Approval for RINVOQ® in Inflammatory Bowel Disease, Boosting Treatment Options
On October 13, 2025, AbbVie announced it received approval from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for...
Piper Sandler Raises AbbVie Price Target to $284, Maintains Overweight Rating
On October 10, 2025, Piper Sandler raised its price target for AbbVie Inc (ABBV) from $231.00 to $284.00 while maintaining an 'Overweight' rating, signaling...